Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
- DOI
- 10.1016/s1470-2045(26)00090-2
- Published
- 2026 Jul
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00090-2,
title = {Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.},
author = {Li Z and Hu J and Chen J and Yu Y and Meng X and Dong X and Hu Y and Ji Y and Liu H and Wang W and Ning F and Zhang Z and Liu C and Zhang Z and Wang Q and Zheng W and Wang H and Qu X and Chen Z and Fan S and Zhang X and Lu S},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(26)00090-2},
url = {https://doi.org/10.1016/s1470-2045(26)00090-2}
}RIS
TY - JOUR TI - Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. AU - Li Z AU - Hu J AU - Chen J AU - Yu Y AU - Meng X AU - Dong X AU - Hu Y AU - Ji Y AU - Liu H AU - Wang W AU - Ning F AU - Zhang Z AU - Liu C AU - Zhang Z AU - Wang Q AU - Zheng W AU - Wang H AU - Qu X AU - Chen Z AU - Fan S AU - Zhang X AU - Lu S PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(26)00090-2 UR - https://doi.org/10.1016/s1470-2045(26)00090-2 ER -
APA
Z, L., J, H., J, C., Y, Y., X, M., X, D., Y, H., Y, J., H, L., W, W., F, N., Z, Z., C, L., Z, Z., Q, W., W, Z., H, W., X, Q., Z, C., S, F., X, Z., & S, L. (2026). Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00090-2
Source records
- pubmed · retrieved 2026-09-27T11:12:51.158Z